NMOSD
Clinical trials for NMOSD explained in plain language.
Never miss a new study
Get alerted when new NMOSD trials appear
Sign up with your email to follow new studies for NMOSD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug aims to stop relapses in kids with rare nerve disease
Disease control Recruiting nowThis study tests a drug called satralizumab in children aged 2-11 with a rare nerve disease called NMOSD. The goal is to see how the drug works in the body and if it can prevent relapses (attacks). About 8 children will take the drug, and researchers will monitor their safety and…
Matched conditions: NMOSD
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New registry to monitor Real-World impact of NMOSD treatments
Knowledge-focused Recruiting nowThis long-term observational registry follows 122 adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor medications (eculizumab or ravulizumab) to prevent relapses. The study collects data on relapse rates, safety, quality of…
Matched conditions: NMOSD
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 04, 2026 16:18 UTC